Deltonin, a steroidal saponin, inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis and antiangiogenesis

Cellular Physiology and Biochemistry

Volumn 27, Issue 3-4, 2011, Pages 233-242

  Tong, Qing Yi ^a   Qing, Yong ^a   Shu, Dan ^a   He, Yang ^a   Zhao, Ying Lan ^a   Li, Yi ^a   Wang, Zhen Ling ^a   Zhang, Shi Yuan ^a   Xing, Zhi Hua ^a   Xu, Cheng ^a   Wei, Yu Quan ^a   Huang, Wen ^a,b   Wu, Xiao Hua ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Anti tumor; Antiangiogenesis; Apoptosis; Colorectal Cancer; Deltonin; Steroidal saponin

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; DELTONIN; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 8; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

DIOSCOREA ZINGIBERENSIS; MURINAE; MUS;

EID: 79953782992     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000327949     Document Type: Article

References (44)

1. Center MM, Jemal A, Smith RA, Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366-378.
2. Lambert R, Sauvaget C, Sankaranarayanan R: Mass screening for colorectal cancer is not justified in most developing countries. Int J Cancer 2009;125:253-256.
3. Coutinho AK, RochaLima CM: Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003;10:224-238. (Pubitemid 36665845)
4. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, Ben-Ze'ev A: Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 2007;67:7703-7712. (Pubitemid 47281363)
5. waf1/cip1 in colon cancer cells. Mol Cancer Ther 2006;5:1459-1466.
6. Zhu J, Guo X, Fu S, Zhang X, Liang X: Characterization of steroidal saponins in crude extracts from Dioscoream zingiberensis C.H.Wright by ultraperformance liquid chromatography/electrospray ionization quadrupole time-of-fighttandem mass spectrometry. J Pharm Biomed Anal 2010;53:462-474.
7. Liu L, Dong YS, Xiu ZL: Three-liquid-phase extraction of diosgenin and steroidal saponins from fermentation of Dioscorea zingibernsis C. H. Wright. Process Biochem 2010;45:752-756.
8. Liu L, Dong YS, Qi SS, Wang H, Xiu ZL: Biotransformation of steriodal saponins in Dioscorea zingiberensis Wright to diosgenin by Trichoderma harzianum. Appl Microbiol Biotechnol 2010;85:933-940
9. Li H, Huang W, Wen YQ, Gong GH, Zhao QB, Yu G: Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis C.H.Wrigh. Fitoterapia 2010;81:1147-1156.
10. Qi SS, Dong YS, Zhao YK, Xiu ZL: Qualitative and quantitative analysis of microbial transformation of steroidal saponins in Dioscorea Zingiberensis. Chromatographia 2008;69:865-870.
11. Wang GX, Jiang DX, Li J, Han J, Liu YT, Liu XL: Anthelmintic activity of steroidal saponins from Dioscorea zingiberensis Wright against Dactylogyrus intermedius (Monogenea) in goldfish (Carassiusauratus). Parasitol Res 2010;107:1365-1371.
12. Sautour M, Mitaine-Offer AC, Lacaille-Dubois MA: The Dioscorea genus: a review of bioactive steroid saponins. J Nat Med 2007;61:91-101.
13. Story MJ, Wayte KM: Methods and compositions for promoting activity of anti-cancer therapies. US patent 20090263504A1, 2009;10-22.
14. Zhang Z, Li M, Wang H, Agrawal S, Zhang R: Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003;100:11636-11641. (Pubitemid 37205988)
15. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y: SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 2008;98:824-831. (Pubitemid 351272602)
16. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S: Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 2005;24:3596-3605. (Pubitemid 40756229)
17. Zheng Y, Zhao YL, Deng X, Yang S, Mao Y, Li Z, Jiang P, Zhao X, Wei Y: Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis. Cancer Invest 2009;27:286-292,
18. Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, Du XB, Wang GQ, Yao WX, Zhao QM, Ye B, Wang R, Diao P, Zhang W, Wu HB, Zhao X, Wei YQ: Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res 2006;12:3193-3199. (Pubitemid 43837369)
19. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, Yoshida O: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-4187.
20. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Deng HX, Li J, Niu T, Yang JL: Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1inmice. J Biol Chem 2003;278:21831-21836. (Pubitemid 36792588)
21. Hoffmann J, Schirner M, Menrad A, Schneider MR: A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginateen- capsulated tumor cells. Cancer Res 1997;57:3847-3851.
22. Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626. (Pubitemid 24064472)
23. Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH, Huynh H: The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004;25:647-659. (Pubitemid 38618516)
24. Cusimano A, Foderà D, D'Alessandro N, Lampiasi N, Azzolina A, Montalto G, Cervello M: Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther 2007;6:1461-1468. (Pubitemid 351590359)
25. Qin Y, Wu X, Huang W, Gong G, Li D, He Y, Zhao Y: Acute toxicity and subchronic toxicity of steroidal saponins from Dioscorea zingiberensis C.H.Wright in rodents. J Ethnopharmacol 2009;126:543-550.
26. Kunnimalaiyaan M, Ndiaye M, Chen H: Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 2006;140:1009-1014.
27. Gong GH, Qin Y, Huang W, Zhou S, Wu XH, Yang XH: Protective effects of diosgenin in the hyperlipidemic rat model and in human vascular endothelial cells against hydrogen peroxide-induced apoptosis. Chemic Biol Interact 2010;184:366-375.
28. McKnight JJ, Gray SB, O'Kane HF, Johnston SR, Williamson KE: Apoptosis and chemotherapy for bladder cancer. J Urol 2005;173:683-690. (Pubitemid 40239320)
29. Rupnow BA, Knox SJ: The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis 1999;4:115-143. (Pubitemid 29378795)
30. Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J: Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 1999;6:25-28. (Pubitemid 29197224)
31. Gartel AL, Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-649.
32. Kim M, Liao J, Dowling ML, Voong KR, Parker SE, Wang S, El-Deiry WS, Kao GD: TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res 2008;68:3440-3449.
33. Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell 2004;116:205-219. (Pubitemid 38167313)
34. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40. (Pubitemid 32225829)
35. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR: Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 2003;5:647-654. (Pubitemid 36818087)
36. Fan TP, Jaggar R, Bicknell R: Controlling the vasculature: angiogenesis, antiangiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995;16:57-66.
37. Isner JM, Asahara T: Therapeutic angiogenesis. Front Biosci 1998;3:49-69.
38. Holaday JW, Berkowitz BA: Antiangiogenic Drugs: Insights into Drug Development from Endostatin, Avastin and Thalidomide. Mol Interven 2009;9:157-166.
39. Paper DH: Natural products as angiogenesis inhibitors. Planta Med 1998;64:686-695.
40. Singh RP, Agarwal R: Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr Cancer Drug Targets 2003;3:205-217. (Pubitemid 36565762)
41. Story MJ, Wayte KM: Methods and compositions for inhibiting angiogenesis. US20090263349A1 2009;10-22.
42. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Ocol 2001;19:2282-2292. (Pubitemid 32366981)
43. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Ocol 2001;19:4097-4106. (Pubitemid 33049527)
44. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, , Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL: Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004;90:1190-1197. (Pubitemid 38496812)